Short answer
DELCATH SYSTEMS, INC. (DCTH) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 references a press release, but the provided text contains no operating or financial results.
DELCATH SYSTEMS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 references a press release, but the provided text contains no operating or financial results
- Disclosure is furnished, not filed, limiting Section 18 liability and incorporation into future SEC filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue rose to $29.1M from $24.2M, led by HEPZATO KIT revenue of $27.1M
- Gross margin expanded to 90% from 86%, supporting strong product economics
- Adjusted EBITDA declined to $7.6M from $9.8M as R&D and commercial expansion spending increased
- 2026 revenue guidance raised to $104M-$108M, implying at least 28% HEPZATO volume growth
- Cash and investments totaled $95.9M with no debt, providing funding for clinical expansion and commercialization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other DELCATH SYSTEMS, INC. 8-K filings
Get the next DCTH 8-K as it lands
Follow DCTH for push alerts, or ask the research agent what this filing means.